PBE vs. ARKG ETF Comparison

Comparison of PowerShares Dynamic Biotech & Genome (PBE) to ARK Genomic Revolution Multi-Sector ETF (ARKG)
PBE

PowerShares Dynamic Biotech & Genome

PBE Description

The PowerShares Dynamic Biotechnology & Genome Portfolio (Fund) is based on the Dynamic Biotech & Genome IntellidexSM Index (Intellidex Index). The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Index. The Intellidex Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value. The Underlying Intellidex Index is comprised of common stocks of 30 US biotechnology and genome companies. These are companies that are principally engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances biotechnology and genetic engineering and reseach. The Fund and the Index are rebalanced and reconstituted quarterly in February, May, August and November.

Grade (RS Rating)

Last Trade

$64.72

Average Daily Volume

13,532

Number of Holdings *

30

* may have additional holdings in another (foreign) market
ARKG

ARK Genomic Revolution Multi-Sector ETF

ARKG Description Companies within ARKG are focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business. The companies held in ARKG may develop, produce or enable: CRISPR Targeted Therapeutics Bioinformatics Molecular Diagnostics Stem Cells Agricultural Biology ARKG will be concentrated in issuers in any industry or group of industries in the health care sector, including issuers having their principal business activities in the biotechnology industry. ARKG is an actively managed ETF that seeks long-term growth of capital by investing under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including health care, information technology, materials, energy and consumer discretionary, that are relevant to the Fund’s investment theme of the genomics revolution.

Grade (RS Rating)

Last Trade

$28.77

Average Daily Volume

2,628,952

Number of Holdings *

38

* may have additional holdings in another (foreign) market
Performance
Period PBE ARKG
30 Days -2.89% -12.73%
60 Days -0.09% -1.15%
90 Days -1.67% -12.28%
12 Months 4.09% -0.43%
5 Overlapping Holdings
Symbol Grade Weight in PBE Weight in ARKG Overlap
AMGN D 4.8% 0.88% 0.88%
IONS F 2.58% 3.7% 2.58%
REGN C 5.02% 1.26% 1.26%
VCYT F 2.31% 2.67% 2.31%
VRTX D 4.85% 2.53% 2.53%
PBE Overweight 25 Positions Relative to ARKG
Symbol Grade Weight
NBIX C 5.32%
TECH F 5.05%
GILD F 4.98%
BIIB F 4.95%
BMRN F 4.66%
MNKD C 3.54%
COLL C 3.31%
CPRX C 3.23%
EXEL B 3.11%
PTCT D 3.11%
TGTX F 3.09%
HALO C 2.99%
UTHR C 2.96%
CLDX C 2.85%
QGEN D 2.73%
RGEN D 2.68%
DVAX F 2.65%
BPMC C 2.64%
MYGN D 2.54%
VCEL B 2.53%
ITCI D 2.49%
XENE D 2.4%
FOLD F 2.29%
EYPT D 2.26%
ACAD F 1.98%
PBE Underweight 33 Positions Relative to ARKG
Symbol Grade Weight
CRSP D -7.72%
RXRX F -6.13%
TWST D -5.78%
EXAS D -5.31%
BEAM C -4.61%
SDGR F -4.07%
NTLA F -3.94%
CDNA C -3.65%
DNA F -3.63%
ARCT D -3.52%
ACCD F -3.36%
TXG F -3.28%
TDOC F -3.08%
VEEV B -2.69%
PACB F -2.68%
VERV D -2.37%
MRNA C -2.27%
NRIX C -2.13%
ADPT F -2.11%
MASS D -1.65%
INCY F -1.58%
QSI C -1.53%
PATH D -1.43%
PRME F -1.34%
CMPS F -1.33%
ABSI C -0.96%
RPTX F -0.88%
CERS F -0.85%
BFLY D -0.77%
NVDA C -0.64%
PSNL D -0.58%
NTRA C -0.47%
GH D -0.4%
Compare ETFs